3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
6
Phase 1/2
3
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasm Metastasis
2
Uveal Melanoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Differentiated Thyroid Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
191
Cisplatin
157
Pemetrexed
152
Paclitaxel
127
Docetaxel
109
pembrolizumab
87
Gemcitabine
73
Erlotinib Hydrochloride
44
Radiotherapy
39
Vinorelbine
35
Gefitinib
34
durvalumab
31
Bevacizumab
28
Nivolumab
26
Drug Therapy
23
atezolizumab
22
osimertinib
19
130-nm albumin-bound paclitaxel
19
tislelizumab
17
Crizotinib
16
Radiosurgery
15
Etoposide
14
Surgical Procedures, Operative
11
Afatinib
11
Ipilimumab
10
icotinib
9
aumolertinib
9
Albumin-Bound Paclitaxel
9
Specimen Handling
8
Observation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Non-Small-Cell Lung
×
AZD 6244
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts